CART cells and MSCs unite
MUNICH & COLOGNE, Germany—A broad partnership has been announced between apceth and the Center for Molecular Medicine Cologne (CMMC) at the University of Cologne for the development of immunotherapies for solid tumors and hematological malignancies. The collaboration will look at combinations of Chimeric Antigen Receptor (CAR) T cells developed in Prof. Hinrich Abken’s lab against multiple tumor-associated antigens and engineered mesenchymal stem cells (MSC) developed by apceth, in hopes of using the MSCs to promote local CART cell activation in tumors. apceth will be responsible for developing and optimizing gmMSCs capable of generating a pro-inflammatory tumor microenvironment, which will be combined with different CART cells developed against cancer-specific markers found on solid tumors and hematological malignancies. No financial details for the deal were disclosed.